Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy
2023 ASCO Genitourinary Cancers Symposium
Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses new data from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The findings suggest that patients whose disease does not respond to bacillus Calmette-Guérin or who declined or were ineligible for a radical cystectomy may benefit from pembrolizumab monotherapy. (Abstract LBA442).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The cohort B of KEYNOTE-057 study investigated pembrolizumab monotherapy in patients with high-risk and non-muscle invasive disease, unresponsive to BCG. The 057 study is a multi-cohort study. The cohort A of the study included the patients with the carcinoma in situ component to with or without papillary disease, unresponsive to BCG who were ineligible for, or declined, radical cystectomy. Results from cohort A presented the clinical complete response rate at 3 months of 40%, with most of the complete responses maintained over time, and resulted in FDA approval of pembrolizumab in the CIS BCG unresponsive population.
The results of cohort B that have been presented at this meeting focused on a bit different patient population, represented by patients without any carcinoma in situ component, and with the only papillary pTa high-grade or any pT1 disease without CIS. This is a very special population for which we do not have any robust standard of care. This is the focus of the cohort B of the study. The design of the study was the same. Pembrolizumab monotherapy until 2 years every 3 weeks or until disease occurrence or progression with high-risk disease. The primary endpoint of this court was 12-month disease-free survival for high-risk disease. Secondary endpoints included the progression-free survival, disease-free survival for any disease occurrence, and the overall survival and quality of life parameters.
The main findings of the KEYNOTE-057 cohort B resulted in 12-month disease-free survival for high-risk disease of almost 43%, which sets among the most robust data already available with this special population. The progression-free survival to any stage progression or stage disease or death was 88%, and progression to muscle-invasive metastatic disease or death was a similar, 88%. There were no new safety signals, no treatment related death. Results, in terms of safety, were consistent with the already available data with pembrolizumab in various disease settings, including cohort A. Quality of life parameters and quality of life scores were maintained over time, were stable over time in patients who continue treatment with or without any recurrence.
So, how can we move forward with this data? Of course, the US FDA requires a randomized study in order to set new standards with newer therapies, and particularly systemic therapies in this special patient population. I think that the data from the cohort B of the study may allow us to re-discuss the need for doing a randomized study in this very difficult to treat population without any robust standard of care intravesical therapy, without any clinical trial option, because of the fact we that we currently lack robust data on standard of care therapies to compare with any newer therapies, intravesically or as a systemic therapy. So I think that the good point of this study is that it will likely generate a new discussion at [inaudible 00:03:21], including regulators, patient advocates, and physicians.
Related Videos
The ASCO Post Staff
Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discusses phase III results from the TALAPRO-2 study, which suggested an improvement in radiographic progression-free survival with the combination of talazoparib and enzalutamide over standard-of-care enzalutamide alone as first-line treatment in patients with metastatic castration-resistant prostate cancer. The improvement was seen regardless of homologous recombination repair gene mutations. The combination regimen delayed the time to chemotherapy and worsening in global health status and quality of life. (Abstract LBA17).
The ASCO Post Staff
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses phase III findings from the KEYNOTE-921 study, which was designed to assess the combination of pembrolizumab and docetaxel in the treatment of patients with metastatic castration-resistant prostate cancer. They had not received chemotherapy, but their disease progressed on the next-generation hormonal agent, or they could not tolerate the agent. (Abstract 19).
The ASCO Post Staff
Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discusses interim results from the CaboPoint study, which evaluated cabozantinib as second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component. Disease in the study participants had progressed after prior treatment with ipilimumab and nivolumab in combination or combined with VEGF-targeted therapy. (Abstract 606).
The ASCO Post Staff
Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the HCRN GU16-260-Cohort A study of patients with previously untreated advanced clear cell renal cell carcinoma who received nivolumab and salvage nivolumab plus ipilimumab. The regimen appears to result in substantial treatment-free survival with few treatment-related adverse events. (Abstract 604).
The ASCO Post Staff
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses results from the FORMULA-509 study, which compared postoperative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide, after radical prostatectomy. The study suggested that adding AAP and apalutamide to salvage radiotherapy, plus 6 months of androgen-deprivation therapy, may improve outcomes, particularly in the subgroup of patients with a prostate-specific antigen level higher than 0.5 ng/mL. (Abstract 303).
